Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSattva S. NeelapuMFMoshe FridmanJWJacob Wulff

Discussion

Loading...

Member takes

Overview

Analysis of surrogate endpoints reveals their impact on long-term outcomes in high-risk large B cell lymphoma patients receiving axicabtagene ciloleucel.

Key Points

  • Patients achieving complete response demonstrated significantly improved long-term outcomes compared to non-completers.
  • At 36 months, overall survival estimates for complete responders were 92.6%, compared to 50.0% for non-responders, with p<0.05.
  • Observational analysis using sensitivity analyses confirmed the significance of complete response at 6 months for predicting long-term outcomes.
  • Overall, results support the utility of surrogate endpoints in clinical trials assessing axi-cel's efficacy for high-risk large B cell lymphoma.

Cite This Study

Neelapu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df49https://doi.org/10.1182/blood-2025-3717
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE2025 · 2 citations
  2. 2Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  3. 3Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel2025
  4. 4Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  5. 5Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025